The proposition that the Southampton ACSC mean SBR of 9.0 could be a close representation of the “true” value is supported by the work by Soret et al [15], which reports a mean of 8.6 in patients suffering from Alzheimer’s disease (this neurodegenerative disease is not characterized by loss of striatal dopamine transporters) obtained by applying, beside ACSC, an individualised MRI-driven partial volume correction [16] to a counts concentration “BRASS-like” calculation of the SBR. This evidence concerns the gene SLC6A3 and neurodegenerative disease.